AI Added to Pulse Oximeters to Monitor Arrhythmia and Respiratory Depression

According to AI TIMES, Masimo received U.S. FDA approval on October 17 and launched the SmartSet platform on the Radius VSM, which combines atrial fibrillation detection with its existing opioid-induced respiratory depression detection. In clinical validation of the atrial fibrillation detection function, sensitivity was reported at 97%. The key point is that pulse oximeters are moving beyond checking a single metric such as oxygen saturation and are being redesigned to read patterns in continuously accumulated physiological signals and detect warning signs earlier. Atrial fibrillation detection identifies the need for further evaluation based on changes in pulse wave rhythm, while respiratory depression is handled through step-by-step alerts by analyzing multiple signals together. The system was presented as a tool to help clinicians compensate for changes that are easy to miss in environments such as general wards or post-operative recovery areas, where intensive monitoring is difficult. However, it is not a device that replaces diagnosis, but an auxiliary tool that supports follow-up testing and clinical judgment, and whether it actually improves outcomes and manages false alarms remains the key to its value in the field.